Susquehanna International Group
CRSP icon

Susquehanna International Group’s CRISPR Therapeutics CRSP Stock Holding History

Susquehanna International Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.2M Sell
593,406
-260,565
-31% -$13.7M ﹤0.01% 1806
2025
Q4 		$44.8M Buy
853,971
+39,647
+5% +$2.37M 0.01% 1453
2025
Q3 		$52.8M Buy
814,324
+44,379
+6% +$2.55M 0.01% 1301
2025
Q2 		$37.5M Buy
769,945
+478,929
+165% +$18.5M 0.01% 1393
2025
Q1 		$9.9M Sell
291,016
-97,299
-25% -$4.12M ﹤0.01% 2547
2024
Q4 		$15.3M Buy
388,315
+29,412
+8% +$1.39M ﹤0.01% 2138
2024
Q3 		$16.9M Buy
358,903
+98,082
+38% +$4.98M ﹤0.01% 2002
2024
Q2 		$14.1M Buy
260,821
+187,583
+256% +$10.9M ﹤0.01% 2094
2024
Q1 		$4.99M Sell
73,238
-143,858
-66% -$10.3M ﹤0.01% 3642
2023
Q4 		$13.6M Buy
217,096
+34,531
+19% +$1.91M ﹤0.01% 2245
2023
Q3 		$8.29M Buy
182,565
+18,846
+12% +$973K ﹤0.01% 2795
2023
Q2 		$9.19M Sell
163,719
-133,070
-45% -$7.55M ﹤0.01% 2616
2023
Q1 		$13.4M Buy
296,789
+214,882
+262% +$10.4M ﹤0.01% 2113
2022
Q4 		$3.33M Buy
81,907
+40,084
+96% +$2.13M ﹤0.01% 3849
2022
Q3 		$2.73M Buy
41,823
+5,006
+14% +$363K ﹤0.01% 4269
2022
Q2 		$2.24M Sell
36,817
-207,914
-85% -$12.2M ﹤0.01% 4678
2022
Q1 		$15.4M Sell
244,731
-331,716
-58% -$20.8M ﹤0.01% 1998
2021
Q4 		$43.7M Buy
576,447
+173,303
+43% +$15.1M 0.01% 1191
2021
Q3 		$45.1M Buy
403,144
+50,971
+14% +$6.4M 0.01% 1232
2021
Q2 		$57M Sell
352,173
-96,716
-22% -$11.8M 0.01% 1113
2021
Q1 		$54.7M Buy
448,889
+282,629
+170% +$42.7M 0.01% 1039
2020
Q4 		$25.5M Buy
166,260
+87,299
+111% +$10.3M ﹤0.01% 1489
2020
Q3 		$6.6M Sell
78,961
-105,081
-57% -$9.32M ﹤0.01% 2718
2020
Q2 		$13.5M Sell
184,042
-19,955
-10% -$1.17M ﹤0.01% 1810
2020
Q1 		$8.65M Buy
203,997
+6,396
+3% +$330K ﹤0.01% 1901
2019
Q4 		$12M Buy
197,601
+75,631
+62% +$4.13M ﹤0.01% 1892
2019
Q3 		$5M Sell
121,970
-60,477
-33% -$2.89M ﹤0.01% 2725
2019
Q2 		$8.59M Sell
182,447
-9,211
-5% -$368K ﹤0.01% 2041
2019
Q1 		$6.85M Sell
191,658
-13,357
-7% -$462K ﹤0.01% 2111
2018
Q4 		$5.86M Sell
205,015
-131,945
-39% -$4.59M ﹤0.01% 2120
2018
Q3 		$14.9M Buy
336,960
+147,022
+77% +$7.7M ﹤0.01% 1565
2018
Q2 		$11.2M Buy
189,938
+32,748
+21% +$1.87M ﹤0.01% 1819
2018
Q1 		$7.18M Buy
157,190
+126,589
+414% +$5.22M ﹤0.01% 2116
2017
Q4 		$719K Buy
30,601
+6,278
+26% +$119K ﹤0.01% 5892
2017
Q3 		$435K Buy
+24,323
New +$441K ﹤0.01% 6752

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Susquehanna International Group's CRSP Position: Q1 2026 in Review

Susquehanna International Group reduced its CRISPR Therapeutics (CRSP) stake by 31% in Q1 2026, selling an estimated $13.7M and leaving 593,406 shares worth $28.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1806.

Susquehanna International Group first reported a position in CRSP in Q3 2017 and has held it in 35 quarters since. The position peaked at $57M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Susquehanna International Group held 593,406 shares of CRISPR Therapeutics worth $28.2M as of Q1 2026.
  • Susquehanna International Group sold 260,565 CRISPR Therapeutics shares in Q1 2026, an estimated $13.7M.
  • CRISPR Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #1806 holding.
  • Susquehanna International Group first reported a position in CRISPR Therapeutics in Q3 2017 and has held it in 35 quarters since.
  • Susquehanna International Group's CRISPR Therapeutics position peaked at $57M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.